Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 104.75
Bid: 104.00
Ask: 105.50
Change: 2.75 (2.69%)
Spread: 1.50 (1.442%)
Open: 102.25
High: 106.00
Low: 103.00
Prev. Close: 102.25
CNC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Supply Agreement

13 Jul 2022 07:00

RNS Number : 2508S
Concurrent Technologies PLC
13 July 2022
 

 

This announcement contains inside information

 

13 July 2022

Concurrent Technologies Plc

("Concurrent Technologies" or the 'Company')

Supply Agreement with Global Medical Technology Company

 

Concurrent Technologies, a world leading specialist in the design and manufacture of high-end embedded computer boards for critical applications, has entered into a supply agreement with a Fortune 500 global medical technology company, and has received an initial USD$2.2 million order for first year product shipments. Initial shipments have already commenced for qualification purposes with volume shipments scheduled to start at the end of 2022. The customer is then expected to place similar size orders on an annual basis for several years to come.

The customer's needs were multi-faceted and challenging. Concurrent Technologies developed a product that maintained backwards compatibility with the external interfaces of the prior product; demonstrated the ability to manage and overcome issues that would prevent multi-year production without changes; and met all the customer's quality and supply chain requirements. Concurrent Technologies also ported the customer's application software to work seamlessly on the new hardware, accelerating the introduction of the customer's next generation machine.

Dr. Miles Adcock, CEO of Concurrent Technologies, commented: "We pride ourselves on delivering extremely reliable products to a very high-quality standard which suits customers from many vertical market segments including medical. The required product was developed at pace in line with the expectation we have set for increasing the cadence of new product introductions. With the customer intending to place similar size orders on an annual basis for several years to come, this is expected to provide a steady revenue stream that is wholly accretive to our current business."

 

Enquiries:

Concurrent Technologies Plc

Miles Adcock, CEO +44 (0)1206 752626

 

SEC Newgate (Financial PR)

Bob Huxford +44 (0)20 3757 6880

Isabelle Smurfit +44 (0)20 3757 6880

Group email concurrent@secnewgate.co.uk

 

Cenkos Securities Plc (NOMAD)

Neil McDonald +44 (0)131 220 9771

Peter Lynch +44 (0)131 220 9772

 

About Concurrent Technologies Plc

Concurrent Technologies Plc develops and manufactures high-end embedded computer products for use in a wide range of high-performance, long-life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments. The processor products feature Intel® processors, including the latest 9th generation embedded Intel® Core™ processors, Intel® Xeon® and Intel® Atom™ processors. The products are designed to be compliant with industry specifications and support many of today's leading embedded Operating Systems. The products are sold world-wide.

For more information on Concurrent Technologies Plc and its products please visit www.gocct.com.

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRSFSEEEEESEDW
Date   Source Headline
16th Aug 20054:15 pmPRNNotice of Results
27th Jul 20051:29 pmRNSShareholder Notification
6th Jul 200511:25 amPRNProduct Launch
30th Jun 20052:30 pmPRNProduct Launch
10th Jun 20055:21 pmRNSProduct Launch
31st May 20053:44 pmRNSDirector Shareholding
24th May 20054:20 pmRNSDirector Shareholding
29th Apr 20054:33 pmRNSAGM Statement
13th Apr 20051:20 pmRNSProduct Launch
4th Apr 20054:02 pmRNSDirector Shareholding
4th Apr 20054:00 pmRNSDirector Shareholding
30th Mar 20054:59 pmRNSDirector Shareholding
22nd Mar 20055:45 pmRNSHolding(s) in Company
21st Mar 20053:00 pmRNSHolding(s) in Company
14th Mar 20057:01 amRNSProduct Launch
7th Mar 20057:01 amRNSFinal Results
7th Mar 20057:00 amRNSGeographical Expansion
25th Feb 20059:25 amRNSProduct Launch
21st Feb 200512:19 pmRNSNotice of Results
2nd Feb 20057:00 amRNSProduct Launch

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.